{"name":"Acurx Pharmaceuticals","slug":"acurx","ticker":"ACXP","exchange":"NASDAQ","domain":"acurxpharma.com","description":"Acurx Pharmaceuticals is a biopharmaceutical company focused on developing novel antibiotics to address the growing threat of antibiotic resistance. The company's lead product candidate, ibezlitam, is a first-in-class antibiotic targeting the bacterial ribosome. Acurx is positioned to capitalize on the significant unmet need for new antibiotics in the market.","hq":"Staten Island, NY","founded":0,"employees":"","ceo":"David P. Luci","sector":"Anti-Infectives / Antibiotics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$42M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":1834506,"netIncome":-7966538,"cash":7689535,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Ibezlitam patent cliff ($0.0B at risk)","drug":"Ibezlitam","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Acurx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Acurx Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, highlighting progress in its pipeline and financial position.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Acurx Pharmaceuticals Announces $20 Million Private Placement Financing","summary":"Acurx Pharmaceuticals announced a private placement financing of $20 million to support the development of its pipeline, including ibezlitam.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Acurx Pharmaceuticals Announces Positive Topline Results from Phase 2 Clinical Trial of Ibezlitam","summary":"Acurx Pharmaceuticals announced positive topline results from its Phase 2 clinical trial of ibezlitam, demonstrating its potential as a novel antibiotic.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNN2J4bEN1UXV0UU02Mk1Rdk5WcWJSdlFSSGdxX1NJLXgteVduMFB3VEU1ZVpFeHVDSmV6amRybU5tX3JiQnFWRFRTSXNILTgwaWlubnkyQlctM2NUdXQxS0VPS2dfM2lFNlhwZ2NTNmZwQl9LQ2ZmeG5vVURlLVpRY1hhQjdqcFdIMXZkUkUwM1BrRkdFYndBcDhaa0d2SDRTZkdvd2lFMTg?oc=5","date":"2026-04-07","type":"pipeline","source":"newswire.com","summary":"New to The Street Resigns Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) to Continue Long-Form Interview Series, Outdoor Media Campaigns and Accredited Investor Events - newswire.com","headline":"New to The Street Resigns Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) to Continue Long-Form Interview Series, Outdoor Medi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE00a0lIcjQ1Y3hrbUpBMmp0by1uTmpBRTY4NU9QRV8zV204QXlqUXpuUU5SYXpPQm8xQ0ViaFQzM1E0bU5JZFFIZzkyWkl5UzZ0OHROUmg5WjZvWU9YUmfSAWNBVV95cUxNTWE2ZWdvSUluTHctOFFlVElSOFk0RDdpUzFMaW1mZ1N2bE5xcDl6OXhKZ0haal9mRE5tQS0xN0l1VWdUakxMcTRld1p6Nng3NlVFbFliX3U3U3ZBWnpuVzNPVEE?oc=5","date":"2026-03-19","type":"pipeline","source":"Bitget","summary":"BBX: \"Hardware Sovereignty\" and \"Pharmaceutical Standard\" Dual Strategy—Bitdeer Sealminer Mass Production, ACXP Establishes 28% Cash Reserve Plan - Bitget","headline":"BBX: \"Hardware Sovereignty\" and \"Pharmaceutical Standard\" Dual Strategy—Bitdeer Sealminer Mass Production, ACXP Establis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQZDRtLWlFTE9DVWxjVFM2dFhILVJocGk2X1R3UTJheHRKNFJzdUQ4WHdKSGhOR1ltdWhJQUZpUVVkU3gxWWtuX0pSVUtpNTBiQ2lpR1N5QWFuVUplenlWQUVuaWxPN1hlRDVEcnc2NFZhSzlYb1ZkRG1xbXNQb3luOUFpUDRJR0xwVjR5N2Z2Z3ZRSUxqTU0tWlZYMTVFZ05KWm5ITzU1azRrU1JjV3NFTVZ3dml4RDdwOVd6ZDZydUJFckttcjBha2ZROXVrb0p0SXNjX3VxdmpkRTgtNkpmcg?oc=5","date":"2026-03-14","type":"deal","source":"The Globe and Mail","summary":"Acurx Pharmaceuticals (ACXP) Gets a Buy from Alliance Global Partners - The Globe and Mail","headline":"Acurx Pharmaceuticals (ACXP) Gets a Buy from Alliance Global Partners","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNTXNFOUhaczlLM1RQWjIzaXVTSVpIWEsyMFBFaVFmd0VGcFlUUU9WMlZQeVpIeTY4Qk5YN21nZUZyMVo0a0s2QUszeDdKLUxZVVRXNXRUdUMtVXJ0ek1DeGlNU0UwajZKZ3dQNkNXdjZJVml5azZaRjQ3WmIzcmVfdVk2S0FPQ3lpeVF3OUxlQjEwWUlKTWtObjVHcU4xeE1PMFVkRUQtTW8tSTdiOW9XTzRRM1o1RzlT?oc=5","date":"2026-03-13","type":"trial","source":"Stock Titan","summary":"Acurx starts recurrent C. diff trial to treat and prevent - Stock Titan","headline":"Acurx starts recurrent C. diff trial to treat and prevent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPXzNGLV94MHhCc05rTXFTWHA5SXgxdjhCZ1VqdUxuWHRvZm1kVjVGeGRkRE1ORzRxeTdTWkZ5M0F1Z2x2dWl5V1JKd2RiaGlEMWpreFRJbGFEZnoxSFQ3V0stUFlrSlFXaXpfdG1COEdVZ1IweDd1SkJmV2sxQnVKUG9iU1R0OEZY?oc=5","date":"2026-03-13","type":"pipeline","source":"timothysykes.com","summary":"Acurx Pharma Stock Dips 9% Amid Market Volatility - timothysykes.com","headline":"Acurx Pharma Stock Dips 9% Amid Market Volatility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOdFNvQlE1V1piNFdyb1MyR1ZBajdoNkN2YXBXVk52Y3JwR3FrYVBlZ3ZlNUVLMUpBeFdvNy02MHBLMlBUWXNLRHhBVGVFaGl1dVVGSXFmOTg2bEFCdHYxa0lsWGFmbnlUcnJ3aGhBanhGYjVZUHhCcUlDZmRhc0lFcDltdXpWcUVXTTBpOWpiaWlQVE45QlItUDJBdHlaR2x1NFFqb2xWTnRyMGtRc1Y1N3F6NGRfMHRqWGlBMkhRTlBCOTU5RmNMcHR6Y3NaOFpWcjJLSXFxaEtrdEpmOUE?oc=5","date":"2026-03-13","type":"earnings","source":"Investing.com","summary":"Earnings call transcript: Acurx Pharmaceuticals Q4 2025 reveals cash boost and R&D progress - Investing.com","headline":"Earnings call transcript: Acurx Pharmaceuticals Q4 2025 reveals cash boost and R&D progress","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSVAtRDJXUFo1eTRnNlhhdHBRRmVPTUcteXVRZktwenhCR1dia0ZhNGdpZlk3X2tpZmQxUU5tUHlIZlVJZ2o4and1SEF0OGhYbGJBTl95WEo0OUR0bW5hVkdjM1pDWFd6bWZTTFV5UjNvZVRDRHBkMEhmOGlzdWYtRDc0ZjRqNUxOcURLRWdqaWpwRmp0ZUpXdm8xLWdfbDRJNjBvMHM0SjNYUXp0cTR0dmRySnJGTUxZT2xF?oc=5","date":"2026-03-11","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Wednesday's After-Market Session - Acurx Pharmaceuticals (NASDAQ:ACXP), A - Benzinga","headline":"12 Health Care Stocks Moving In Wednesday's After-Market Session - Acurx Pharmaceuticals (NASDAQ:ACXP), A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPVGlXcXZONkI5V1JjSEFVaHkxckdyU3cta3c3RXpZMnZPczRVVzM0czhhU3pjd0dobzJQQ2hvMGU5djFsOU03MGdaeHVHMktzcHJWQXhPemt1VHE4a2xBb0ptY3dIS0lIRDVDTjZjak1uem5XVGxfbjlBVU9XRUx1UW05WWt0WWZH?oc=5","date":"2026-03-11","type":"trial","source":"timothysykes.com","summary":"Acurx Launches Revolutionary Trials for C. difficile Drug - timothysykes.com","headline":"Acurx Launches Revolutionary Trials for C. difficile Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOS1NOUUt1QmlmSk1RMTlRMks3YzJlZ21hVlk3d2xhdElIaFFoWXk1MVZEZFV3QnFPaTJ4N2p6R2FJQ29XUy13bF9jZmpWYlM2VWk1OHZrT0g5T2VLaG8ycHk3WTVQZF8ycG13Z1p6Q082Y2tXVEdYSGNQWUxHeTZNeVBCdVQ2RFBTQ2ZiLUZmc3JYYjlmbUR5ZlFDdlJOemJqbWRfTVY4VHFPbTRnQVhwSTZn?oc=5","date":"2026-03-09","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Monday's Intraday Session - Acurx Pharmaceuticals (NASDAQ:ACXP), Firefly - Benzinga","headline":"12 Health Care Stocks Moving In Monday's Intraday Session - Acurx Pharmaceuticals (NASDAQ:ACXP), Firefly","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNQmIxN25wdTB0X1lxRHBuUkZFLVZnbW1CM1E1UmlhTVREVGN6cDVQN0t6aktaVzFuTEdrLWhVdEFCUGtPWjZjWmRwUUpmd1hDTDJaQ19uVHNrM2dIVHEzZ0dTTklJUVczWGdUb2RGb2RRSlB0Sk9rVk5IakJMQ1lkT0tycEx5UW9xTVo3bERGVUVVNHVsbTJLaGpfNFBKUmNNbmxNMS1JWGxQMndYTzJRbkN1MFBHdE56T09Z?oc=5","date":"2026-02-02","type":"patent","source":"Stock Titan","summary":"Acurx patent backs new antibiotics for C. diff and MRSA - Stock Titan","headline":"Acurx patent backs new antibiotics for C. diff and MRSA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxORjN4QUM0dWdZS1MtLXNsTFlzN3VMUGhmenU4VHJaYjRLWDBtaDFJWGQwYmpLY2U1dW5VX3VtTlMwNWdKZEE2X0phMTRRdWdxU04ySG1VN0JSbWM3aEE5dUVhZVNNNUVqdlVuM2VRNHpjX3k5QTZFeXJoaXM1OHhKRThjN2x4S19ROTVR?oc=5","date":"2026-01-21","type":"pipeline","source":"Yahoo Finance","summary":"Loss-Making Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Expected To Breakeven In The Medium-Term - Yahoo Finance","headline":"Loss-Making Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Expected To Breakeven In The Medium-Term","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE1HU0l6VTc0bzI2RE9xMEVMNlNDSFI4MGdZOVh3NDJJUERhdHdRamJWVVZSTFRReFppM3kzX2IzMUhPSHQ3dlRmR2pGcnRNRGlOQVYxcEhwVkx1YUtseUpWcERHYWtIcngtaWltbkF3RWFTNjQ?oc=5","date":"2025-09-26","type":"pipeline","source":"Hilton Head Island Packet","summary":"New to The Street to Broadcast Saturday, September 27th Featuring NeOnc Pharma $NTHI and Other Innovative Companies - Hilton Head Island Packet","headline":"New to The Street to Broadcast Saturday, September 27th Featuring NeOnc Pharma $NTHI and Other Innovative Companies","sentiment":"neutral"}],"patents":[{"drugName":"Ibezlitam","drugSlug":"ibezlitam","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Merck & Co.","Gilead Sciences"],"therapeuticFocus":["Anti-Infectives / Antibiotics"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":1834506,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-7966538,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":7689535,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}